New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting : vimarsana.com

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant LDL-C reduction vs. clinician-determined usual care (60% vs. 7% respectively)1 A significantly greater proportion of the ASCVD patients receiving Leqvio achieved guideline-recommended LDL-C goal vs. the usual care arm […]

Related Keywords

United States , South Korea , Switzerland , China , Netherlands , Amsterdam , Noord Holland , Japan , America , American , Swiss , Han , Michael Meo , Marlena Abdinoor , Michael Koren , Parag Mahanti , Jonathan Graham , Sloan Simpson , Coll Cardiol , Health Promotion Series , Alnylam Pharmaceuticals , American Heart Association , European Medicines Agency , Novartis Pharmaceuticals Corp , American College Of Cardiology Congress , American College Of Cardiology Heart Association , National Medical Products Administration , World Heart Federation , Clinical Research , Journal Of The American College Cardiology , Instagram , Novartis , European Union , Exchange Commission , Facebook , European Society Of Cardiology Congress , Linkedin , Novartis Pharmaceuticals Corporation , World Health Organization , Jacksonville Center , Public Health , Annual Scientific Session , American College , Medical Director , Safety Information , Atherosclerotic Cardiovascular Disease , Cardiology Congress , European Society , Medical Products , American Heart , American Heart Association Task Force , Clinical Practice , World Heart , Published May ,